<div id="readability-page-1"><div><p><span>SSY Group Ltd </span><span>:</span></p><ul><li>SSY GROUP SEES REDUCTION IN FY PROFIT ATTRIBUTABLE IN RANGE OF 45% TO 60%</li><li>EXPECTED RESULT DUE TO DECLINE IN TURNOVER, OTHERS IN FY</li></ul></div></div>

159570

516500

520880

<p>SSY Group Ltd :SSY GROUP SEES REDUCTION IN FY PROFIT ATTRIBUTABLE IN RANGE OF 45% TO 60%EXPECTED RESULT DUE TO DECLINE IN TURNOVER, OTHERS IN FY</p>

Reuters

China Universal CNI HK Connect Innovative Drugs Industry ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

CSPC PHARMA

China Merchants CSI Biotechnology Theme ETF

CSPC Innovation

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng Health Care ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Hwabao WP CSI Pharmaceuticals ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund CSI 300 Health Care ETF

Yinhua CSI Innovative Drugs Industry ETF

Penghua CSI HK Connect Health Care Composite ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

SSY Group Sees Reduction In FY Profit Attributable In Range Of 45% To 60%